"Amgen’s Phase III trial of Imdelltra meets primary endpoint for SCLC" was originally created and published by Clinical ...

Amgen (AMGN) announced that the global Phase 3 DeLLphi-304 clinical trial evaluating Imdelltra as a treatment for patients with small cell lung ...

Amgen has shared positive results from a late-stage study of its immunotherapy Imdelltra (tarlatamab-dlle) in small cell lung cancer (SCLC). The global DeLLphi-304 trial has been comparing the drug ...

Amgen (NasdaqGS:AMGN) made considerable strides in its oncology portfolio, as evidenced by the successful interim results for ...

Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who ...

Tarlatamab-dlle significantly improves overall survival in SCLC compared to standard chemotherapy, as demonstrated in the phase 3 DeLLphi-304 trial. The bispecific T-cell engager targets DLL3 on ...

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

Amgen (NASDAQ:AMGN), a biotechnology leader with a market capitalization of $151.3 billion and impressive gross margins of nearly 69%, reported that its Phase 3 DeLLphi-304 clinical trial ...

1 The topline results from DeLLphi-304 demonstrate overwhelming clinical benefit for people living with this devastating disease and affirm IMDELLTRA as standard of care," said Jay Bradner ...

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a biotechnology leader with a market capitalization of $151.3 billion and impressive gross margins of nearly 69%, reported that its Phase 3 DeLLphi-304 ...

April 11, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with ...